



PRESS RELEASE

For more information contact:
Jean Golden/612-385-2324
PR@v2r.com

ICU Data Systems, A V2R Group Portfolio Company, Announces *iCuro*® Chosen To Play Key Role in Somanetics Clinical Trial at University of Florida Shands Children's Hospital

ORLANDO, FL (April 2, 2008) — ICU Data Systems, Inc. (www.icudata.com), a provider of critical care medical technology solutions, announced today that the company's *iCuro*® (ICU Real-time Observer) has been selected to participate in a clinical trial of the Somanetics (NASDAQ: SMTS) INVOS® Cerebral/Somatic Oximeter, to be conducted in the Level 3 neonatal intensive care unit in Shands Children's Hospital at the University of Florida effective March 2008.

Willa Drummond, MD, MS, Chief Medical Information Executive of ICU Data Systems, will be the Principal Investigator on the Clinical Preference Evaluation, which will run for 30 days to assess the utility of the OxyAlert™ NIRSensor for non-invasively and continually monitoring oxygen levels in the brain of premature infants in neonatal intensive care.

ICU Data Systems' *iCuro* will provide the critical care links to medical technology being used for monitoring and care in real-time. The *iCuro* link will provide minute by minute data regarding influences of many different conditions and treatments that influence brain oxygenation during the evaluation. *iCuro* will integrate and chart the real-time data from several individual monitors being used at the infant's bedside, with data from the INVOS System. By automating clinical data entry, aggregation and re-presentation to bedside caregivers during the trial, *iCuro* will virtually eliminate the time that ICU caregivers spend typing. Charting errors may also be greatly decreased, allowing improved data based decision making by caregivers overall during the trial.

According to Dr. Drummond, "On many levels, *iCuro* offers important technological breakthroughs for clinical settings in all intensive care units. The advancement of being able to monitor premature infants in neonatal intensive care units is a long-awaited milestone. The pairing of these two next generation devices, enables physicians, nurses, and other caregivers to monitor and utilize up to the minute integrated patient data. The new methods are a great improvement over the current method of relying on hourly manual recording from a paper flow sheet. *iCuro* is especially powerful in this situation because it simultaneously stores and displays data from virtually all of the monitors and equipment at the patient's bedside, giving us access to a wealth of critical information on an ongoing basis, diminishing the likelihood of bias and error that accompanies traditional bedside charting."

-More-

Dr. Drummond continued, “Typically, premature infants are highly complex patients who have multiple medical problems simultaneously. The new technology for monitoring premature brain and other organ blood flow promises not only to help us better understand what in our care affects brain, kidney, liver and intestinal blood flow, but also will help us tailor more effective and powerful interventions in the future, ultimately leading to significant advances in treatment and outcome. Lastly, not only will the INVOS System which can be connected to *iCuro* help improve patient care, but it also will be very likely to improve the economic performance of hospitals in the process.”

“We are honored and excited to have *iCuro* chosen for this evaluation, not only because of the important work for which Dr. Drummond is known, but also because we believe *iCuro* has the potential to revolutionize the analysis of data and patient trends, an ability not available to caregivers before the advent of *iCuro*,” said Lori Frank, ICU Data Systems Chief Executive Officer. “Its applications extend far beyond research and neonatal care to anywhere real time bedside clinical data is relevant - basically anywhere patients have multiple symptoms that would benefit from integrating multidimensional data instantly.”

V2R Group Chairman and CEO Bahram Yusefzadeh added, “Playing a key role in this clinical trial is another indicator that ICU Data Systems is revolutionizing the way hospitals chart and analyze patient data. The *iCuro* technology is unsurpassed and serves as a leader in the movement of ICU units nationwide to integrate patient data to the Electronic Medical Records as standard operating procedure.”

About Dr. Willa Drummond

Willa H. Drummond, MD, MS (Medical Informatics), is an internationally recognized and distinguished physician with wide experience and knowledge on the topic of Medical Informatics in Intensive Care Unit applications. She is also a noted and published author on Neonatal Care.

About ICU Data Systems, Inc.

ICU Data Systems, a portfolio company of V2R Group, Inc., is a provider of critical care medical technology solutions, with offices in Orlando and Gainesville, Florida, and Minneapolis, Minnesota. The company’s flagship product, *iCuro*[®] is a unique, automated real-time bedside clinical data management solution for bedside clinicians in intensive care units. This cost-effective data solution supersedes the hourly manual charting methods used today, by capturing and centralizing patient data in real time from multiple clinical data sources. Utilizing its proprietary and patented technology, ICU Data Systems also enables the intensive care units of hospitals to easily comply with JCAHO standards and HIPAA mandates. For more information, visit: www.icudata.com.

About V2R Group, Inc.

V2R Group, the parent company of ICU Data Systems, focuses on the commercialization and management of highly innovative technologies. A key element of the V2R business model is to partner with universities to facilitate the transfer and commercialization of revolutionary technologies, with a focus on mid-stage high-tech businesses that have been developed past the initial research and development stage. V2R is led by a management team with many years of experience in technology commercialization and business. For more information: visit: www.v2r.com.

###

iCuro[®] was developed by a team of scientists at The University of Florida Colleges of Medicine & Engineering. Portions of the funding for the initial research and development were provided by National Medical Technology Testbed (NMTB), an organization funded by the Department of the Army under Cooperative Agreement DAMD17-97-2-7016.

Note to Editors: For more information, photography and interviews, please contact Jean Golden at PR@V2R.COM or 612-385-2324.